Blockade of the epidermal growth factor receptor inhibits transforming growth factor α-lnduced but not estrogen-induced growth of hormone-dependent human breast cancer

Carlos L. Arteaga, Ester Coronado, C. Kent Osborne

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Transforming growth factor α (TGFα), a polypeptide that binds to the epidermal growth factor (EGF) receptor, is expressed and secreted by human breast cancer cells and has been proposed as an autocrine growth factor and as a mediator of the mitogenic effect of estrogen. We investigated the potential importance of secreted TGFα in estrogen- responsive MCF-7 human breast cancer cells using monoclonal (528ab and 225ab) and polyclonal antibodies that block the EGF/TGFα receptor. Confirming other studies, these MCF-7 cells expressed TGFα with mRNA transcripts of 4.8 kilobases identified by Northern analysis, and they secreted TGFa activity measured by normal rat kidney colony-forming assay and an EGF RRA of conditioned medium. This activity was increased 3-fold by 1 nwi 17β- estradiol and decreased by 1 μm tamoxifen. 528ab and 225ab bound to EGF receptors in MCF-7 cells with high affinity [dissociation constant (Kd) 0.1-0.5 nM] and blocked the binding of EGF/TGFα. These antibodies failed to inhibit baseline DNA synthesis or growth of MCF-7 cells although they were potent inhibitors of EGF/TGFα-induced growth of these cells. We hypothesized that if secreted TGFa mediates estrogen-induced growth, then EGF/TGFα receptor blockade should inhibit estrogen stimulation. MCF-7 cells were first treated with tamoxifen to inhibit growth and to reduce TGFα expression. Under these conditions, estrogen replenishment induced a marked dose-dependent rescue of TGFα secretion, DNA synthesis, and cell proliferation. Exogenous TGFα also partially restored growth of tamoxifen- inhibited cells. Although the simultaneous addition of 528ab or 225ab blocked TGFα-induced rescue of MCF-7 cells, it had no effect on rescue by estradiol. Similar results were observed with a polyclonal anti- EGF receptor antibody, and with two other estrogen- responsive breast cancer cell lines. In summary, blockade of the EGF/TGFα receptor in hormone- dependent human breast cancer cells does not alter estrogen-regulated growth suggesting that secreted TGFα is not a primary mediator of the growth effects of estrogen.

Original languageEnglish (US)
Pages (from-to)1064-1069
Number of pages6
JournalMolecular Endocrinology
Volume2
Issue number11
DOIs
StatePublished - Jan 1 1988

Fingerprint

Human Growth Hormone
Transforming Growth Factors
Epidermal Growth Factor Receptor
Estrogens
Breast Neoplasms
Epidermal Growth Factor
MCF-7 Cells
Growth
Growth Factor Receptors
Tamoxifen
Antibodies
Estradiol
DNA
Conditioned Culture Medium
Intercellular Signaling Peptides and Proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

@article{fb795a376a8647d2934ea00e638a2232,
title = "Blockade of the epidermal growth factor receptor inhibits transforming growth factor α-lnduced but not estrogen-induced growth of hormone-dependent human breast cancer",
abstract = "Transforming growth factor α (TGFα), a polypeptide that binds to the epidermal growth factor (EGF) receptor, is expressed and secreted by human breast cancer cells and has been proposed as an autocrine growth factor and as a mediator of the mitogenic effect of estrogen. We investigated the potential importance of secreted TGFα in estrogen- responsive MCF-7 human breast cancer cells using monoclonal (528ab and 225ab) and polyclonal antibodies that block the EGF/TGFα receptor. Confirming other studies, these MCF-7 cells expressed TGFα with mRNA transcripts of 4.8 kilobases identified by Northern analysis, and they secreted TGFa activity measured by normal rat kidney colony-forming assay and an EGF RRA of conditioned medium. This activity was increased 3-fold by 1 nwi 17β- estradiol and decreased by 1 μm tamoxifen. 528ab and 225ab bound to EGF receptors in MCF-7 cells with high affinity [dissociation constant (Kd) 0.1-0.5 nM] and blocked the binding of EGF/TGFα. These antibodies failed to inhibit baseline DNA synthesis or growth of MCF-7 cells although they were potent inhibitors of EGF/TGFα-induced growth of these cells. We hypothesized that if secreted TGFa mediates estrogen-induced growth, then EGF/TGFα receptor blockade should inhibit estrogen stimulation. MCF-7 cells were first treated with tamoxifen to inhibit growth and to reduce TGFα expression. Under these conditions, estrogen replenishment induced a marked dose-dependent rescue of TGFα secretion, DNA synthesis, and cell proliferation. Exogenous TGFα also partially restored growth of tamoxifen- inhibited cells. Although the simultaneous addition of 528ab or 225ab blocked TGFα-induced rescue of MCF-7 cells, it had no effect on rescue by estradiol. Similar results were observed with a polyclonal anti- EGF receptor antibody, and with two other estrogen- responsive breast cancer cell lines. In summary, blockade of the EGF/TGFα receptor in hormone- dependent human breast cancer cells does not alter estrogen-regulated growth suggesting that secreted TGFα is not a primary mediator of the growth effects of estrogen.",
author = "Arteaga, {Carlos L.} and Ester Coronado and Osborne, {C. Kent}",
year = "1988",
month = "1",
day = "1",
doi = "10.1210/mend-2-11-1064",
language = "English (US)",
volume = "2",
pages = "1064--1069",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Blockade of the epidermal growth factor receptor inhibits transforming growth factor α-lnduced but not estrogen-induced growth of hormone-dependent human breast cancer

AU - Arteaga, Carlos L.

AU - Coronado, Ester

AU - Osborne, C. Kent

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Transforming growth factor α (TGFα), a polypeptide that binds to the epidermal growth factor (EGF) receptor, is expressed and secreted by human breast cancer cells and has been proposed as an autocrine growth factor and as a mediator of the mitogenic effect of estrogen. We investigated the potential importance of secreted TGFα in estrogen- responsive MCF-7 human breast cancer cells using monoclonal (528ab and 225ab) and polyclonal antibodies that block the EGF/TGFα receptor. Confirming other studies, these MCF-7 cells expressed TGFα with mRNA transcripts of 4.8 kilobases identified by Northern analysis, and they secreted TGFa activity measured by normal rat kidney colony-forming assay and an EGF RRA of conditioned medium. This activity was increased 3-fold by 1 nwi 17β- estradiol and decreased by 1 μm tamoxifen. 528ab and 225ab bound to EGF receptors in MCF-7 cells with high affinity [dissociation constant (Kd) 0.1-0.5 nM] and blocked the binding of EGF/TGFα. These antibodies failed to inhibit baseline DNA synthesis or growth of MCF-7 cells although they were potent inhibitors of EGF/TGFα-induced growth of these cells. We hypothesized that if secreted TGFa mediates estrogen-induced growth, then EGF/TGFα receptor blockade should inhibit estrogen stimulation. MCF-7 cells were first treated with tamoxifen to inhibit growth and to reduce TGFα expression. Under these conditions, estrogen replenishment induced a marked dose-dependent rescue of TGFα secretion, DNA synthesis, and cell proliferation. Exogenous TGFα also partially restored growth of tamoxifen- inhibited cells. Although the simultaneous addition of 528ab or 225ab blocked TGFα-induced rescue of MCF-7 cells, it had no effect on rescue by estradiol. Similar results were observed with a polyclonal anti- EGF receptor antibody, and with two other estrogen- responsive breast cancer cell lines. In summary, blockade of the EGF/TGFα receptor in hormone- dependent human breast cancer cells does not alter estrogen-regulated growth suggesting that secreted TGFα is not a primary mediator of the growth effects of estrogen.

AB - Transforming growth factor α (TGFα), a polypeptide that binds to the epidermal growth factor (EGF) receptor, is expressed and secreted by human breast cancer cells and has been proposed as an autocrine growth factor and as a mediator of the mitogenic effect of estrogen. We investigated the potential importance of secreted TGFα in estrogen- responsive MCF-7 human breast cancer cells using monoclonal (528ab and 225ab) and polyclonal antibodies that block the EGF/TGFα receptor. Confirming other studies, these MCF-7 cells expressed TGFα with mRNA transcripts of 4.8 kilobases identified by Northern analysis, and they secreted TGFa activity measured by normal rat kidney colony-forming assay and an EGF RRA of conditioned medium. This activity was increased 3-fold by 1 nwi 17β- estradiol and decreased by 1 μm tamoxifen. 528ab and 225ab bound to EGF receptors in MCF-7 cells with high affinity [dissociation constant (Kd) 0.1-0.5 nM] and blocked the binding of EGF/TGFα. These antibodies failed to inhibit baseline DNA synthesis or growth of MCF-7 cells although they were potent inhibitors of EGF/TGFα-induced growth of these cells. We hypothesized that if secreted TGFa mediates estrogen-induced growth, then EGF/TGFα receptor blockade should inhibit estrogen stimulation. MCF-7 cells were first treated with tamoxifen to inhibit growth and to reduce TGFα expression. Under these conditions, estrogen replenishment induced a marked dose-dependent rescue of TGFα secretion, DNA synthesis, and cell proliferation. Exogenous TGFα also partially restored growth of tamoxifen- inhibited cells. Although the simultaneous addition of 528ab or 225ab blocked TGFα-induced rescue of MCF-7 cells, it had no effect on rescue by estradiol. Similar results were observed with a polyclonal anti- EGF receptor antibody, and with two other estrogen- responsive breast cancer cell lines. In summary, blockade of the EGF/TGFα receptor in hormone- dependent human breast cancer cells does not alter estrogen-regulated growth suggesting that secreted TGFα is not a primary mediator of the growth effects of estrogen.

UR - http://www.scopus.com/inward/record.url?scp=0023725888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023725888&partnerID=8YFLogxK

U2 - 10.1210/mend-2-11-1064

DO - 10.1210/mend-2-11-1064

M3 - Article

C2 - 3221874

AN - SCOPUS:0023725888

VL - 2

SP - 1064

EP - 1069

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 11

ER -